Igenomix ERA Calculator

ERA-guided embryo transfers demonstrate significantly improved success rates compared to standard timing, particularly for patients with previous implantation failures. For patients with repeated implantation failure (2+ previous failed transfers), pregnancy rates typically improve from approximately 25% with standard timing to 50% with personalized ERA-guided timing – representing a 100% relative improvement. For the general IVF population, pregnancy rates show more modest but still meaningful improvement from approximately 45% to 55%. The greatest benefits are observed in patients found to have non-receptive endometrium at standard timing (approximately 30% of all patients tested), where personalized timing adjustment can increase pregnancy rates by 60-150% depending on the specific displacement identified. Success rates also vary based on additional factors including embryo quality, maternal age, and other infertility diagnoses. It’s important to note that ERA testing optimizes timing but doesn’t address other potential implantation barriers, so comprehensive fertility evaluation remains essential.

The complete ERA testing process typically requires 6-8 weeks from initial consultation to receipt of results and development of a personalized transfer plan. The timeline breaks down as follows: Initial consultation and cycle planning (1-2 weeks), hormonal preparation for the mock cycle (2-3 weeks), precise timing of the endometrial biopsy (1 day), laboratory analysis and result generation (2-3 weeks), and follow-up consultation to review results and plan the personalized transfer cycle (1 week). The actual biopsy procedure itself takes only 5-10 minutes and is performed in the clinic without anesthesia. Patients should plan for the testing cycle to be a “mock” or practice cycle that doesn’t involve actual embryo transfer, followed by a separate treatment cycle for the personalized embryo transfer once results are available. Some clinics offer expedited processing for urgent cases, but standard timing allows for thorough analysis and accurate results. The entire process requires careful coordination with the menstrual cycle, so starting at the beginning of a cycle is necessary for proper timing.

The ERA biopsy procedure typically causes mild to moderate discomfort similar to menstrual cramps, but is generally well-tolerated by most patients without anesthesia. During the procedure: You’ll lie in the same position as for a Pap smear, a speculum is inserted to visualize the cervix, the cervix may be cleansed with a solution, a thin, flexible catheter (pipelle) is passed through the cervix into the uterine cavity, and a small sample of endometrial tissue is collected by gentle suction. The entire procedure takes 5-10 minutes. Most patients describe the sensation as strong menstrual cramps that last for 30-60 seconds during the actual tissue collection. Some clinics recommend taking ibuprofen or similar medication about an hour before the procedure to minimize discomfort. After the biopsy, you might experience mild cramping or light spotting for a day or two. Serious complications are rare but can include infection, significant bleeding, or vasovagal reaction. The sample adequacy rate is over 98%, meaning repeat procedures are rarely needed. If you have a history of cervical stenosis or find pelvic exams particularly uncomfortable, discuss pain management options with your doctor beforehand, as some patients may benefit from cervical softening medication or mild sedation.

The ERA test demonstrates high accuracy in predicting endometrial receptivity, with clinical validation studies showing approximately 95.6% accuracy in classifying receptivity status. The test’s predictive value is based on extensive research involving gene expression analysis of 236 markers associated with the window of implantation. Analytical validation shows 99.9% precision in gene expression measurement and 98.7% reproducibility when tests are repeated. The algorithm was trained on a large database of known receptivity states and has been clinically validated in multiple independent studies. However, it’s important to understand what this accuracy means: The test accurately identifies whether the endometrium is receptive at the specific timing of the biopsy (120 hours after progesterone initiation in a standardized cycle). It doesn’t guarantee pregnancy, as many other factors affect implantation success. The accuracy also assumes proper sample collection, handling, and processing. In about 2% of cases, results may be inconclusive due to sample issues, requiring repeat testing. For patients with non-receptive results who undergo personalized transfer timing, subsequent pregnancy rates increase significantly, providing indirect validation of the test’s clinical utility. The test’s high accuracy makes it a valuable tool, but it should be interpreted as part of a comprehensive fertility evaluation.

Yes, ERA testing can and often should be combined with PGT-A (preimplantation genetic testing for aneuploidy) for comprehensive embryo and endometrial assessment, particularly in cases of repeated implantation failure or advanced maternal age. These two tests address different aspects of implantation: PGT-A evaluates embryonic factors by assessing chromosome normality, while ERA evaluates endometrial factors by determining optimal transfer timing. Using both tests together provides a more complete picture of potential implantation barriers. The typical sequence involves: performing PGT-A on embryos to identify euploid (chromosomally normal) embryos, conducting ERA testing in a separate mock cycle to determine personalized transfer timing, and then transferring a euploid embryo in a subsequent treatment cycle using the personalized timing determined by ERA. This combined approach has shown particularly promising results for patients with previous implantation failures, where addressing both embryonic and endometrial factors can significantly improve success rates. Some studies suggest pregnancy rates of 60-70% when transferring euploid embryos using ERA-determined personalized timing in appropriate patient populations. However, both tests add cost and time to treatment, so the decision to use both should be based on individual patient factors, age, previous treatment history, and specific clinical circumstances.

Current evidence suggests that ERA results remain valid for approximately 2-3 years for most patients, though individual factors may influence this timeline. The stability of the endometrial receptivity signature appears relatively consistent across multiple cycles in the majority of women. Research indicates that about 90% of patients show consistent receptivity status when retested after 12-18 months, and approximately 85% maintain the same status after 2-3 years. However, certain factors may necessitate retesting: significant changes in body weight (gain or loss of >10% body weight), major hormonal changes (such as after ovarian surgery or certain medications), advancing age (particularly after 40-42), development of new uterine pathology (such as polyps or fibroids), or if several years have passed since the original test. Additionally, if a patient has a successful pregnancy followed by attempts for another child years later, retesting may be recommended as hormonal and endometrial environments can change postpartum. For patients with initially non-receptive results who undergo successful personalized transfers, the same timing adjustment is typically used for subsequent transfers within the 2-3 year window. However, if implantation fails despite personalized timing, retesting or additional evaluation may be warranted. Your reproductive specialist can provide personalized guidance based on your specific situation and time elapsed since testing.

ERA, EMMA, and ALICE are complementary endometrial diagnostic tests that evaluate different aspects of endometrial health using the same biopsy sample: ERA (Endometrial Receptivity Analysis) assesses the timing of the window of implantation by analyzing the gene expression profile of 236 markers to determine if the endometrium is receptive, pre-receptive, or post-receptive at the time of biopsy. EMMA (Endometrial Microbiome Metagenomic Analysis) evaluates the composition of the endometrial microbiome, specifically looking for optimal lactobacillus dominance (≥90%) versus potentially problematic bacteria that might create an inflammatory environment hostile to implantation. ALICE (Analysis of Infectious Chronic Endometritis) detects specific pathogens associated with chronic endometritis, a condition of uterine inflammation that can impair implantation and is often asymptomatic. While ERA focuses on timing, EMMA and ALICE focus on the endometrial environment. All three tests can be performed on the same biopsy sample, providing comprehensive endometrial evaluation. The combined approach is particularly valuable for patients with repeated implantation failure, as it can identify multiple potential issues: displaced implantation window (ERA), dysbiotic microbiome (EMMA), and/or chronic infection (ALICE). Treatment can then be tailored accordingly: personalized transfer timing for ERA issues, probiotics or antibiotics for microbiome issues (EMMA), and specific antibiotic regimens for infectious causes (ALICE). This comprehensive diagnostic approach addresses multiple potential implantation barriers simultaneously.

Insurance coverage for ERA testing varies significantly between providers and plans, with many considering it an elective or experimental procedure and providing limited or no coverage. Currently, only a minority of insurance plans routinely cover ERA testing, though coverage is gradually expanding as more evidence demonstrates its clinical utility. Factors influencing coverage include: the specific insurance provider and plan details, the patient’s diagnosis (coverage is more likely for documented repeated implantation failure), state mandates for fertility coverage, and whether the provider is in-network or out-of-network. Out-of-pocket costs for ERA testing typically range from $800 to $1,200, with additional costs for the mock cycle medications, monitoring appointments, and biopsy procedure. Some clinics offer package pricing or financing options. For patients with coverage denials, options include: appealing the decision with additional medical documentation, using flexible spending account (FSA) or health savings account (HSA) funds, investigating clinical trials that might offer testing at reduced cost, or discussing payment plans with the clinic. It’s important to verify benefits specifically for “endometrial receptivity analysis” or “ERA testing” with your insurance provider before proceeding, as coverage terms can be complex. Some patients choose to proceed with self-pay when improved success rates justify the investment, particularly when previous cycles have failed and the potential benefit is significant.